PBA
RVMD icon

Paradigm Biocapital Advisors’s Revolution Medicines RVMD Stock Holding History

Paradigm Biocapital Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$647M Buy
6,655,703
+11,300
+0.2% +$1.14M 13.23% 2
2025
Q4 		$529M Buy
6,644,403
+421,112
+7% +$27.6M 13.51% 2
2025
Q3 		$291M Buy
6,223,291
+130,000
+2% +$5.09M 8.27% 4
2025
Q2 		$224M Sell
6,093,291
-84,820
-1% -$3.26M 9.57% 4
2025
Q1 		$218M Sell
6,178,111
-375,000
-6% -$15.2M 10.01% 3
2024
Q4 		$287M Buy
6,553,111
+1,239,022
+23% +$62.5M 9.97% 4
2024
Q3 		$241M Buy
5,314,089
+55,000
+1% +$2.39M 8.15% 4
2024
Q2 		$204M Buy
5,259,089
+2,344,114
+80% +$87.6M 7.81% 4
2024
Q1 		$93.9M Buy
+2,914,975
New +$86.4M 3.31% 13

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Paradigm Biocapital Advisors's RVMD Position: Q1 2026 in Review

Paradigm Biocapital Advisors increased its Revolution Medicines (RVMD) stake by 0.17% in Q1 2026, buying an estimated $1.14M and bringing the position to 6,655,703 shares worth $647M. The position accounts for 13.23% of the portfolio, ranked #2.

Paradigm Biocapital Advisors first reported a position in RVMD in Q1 2024 and has held it in 9 quarters since. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • Paradigm Biocapital Advisors held 6,655,703 shares of Revolution Medicines worth $647M as of Q1 2026.
  • Paradigm Biocapital Advisors bought 11,300 Revolution Medicines shares in Q1 2026, an estimated $1.14M.
  • Revolution Medicines made up 13.23% of Paradigm Biocapital Advisors's portfolio in Q1 2026, its #2 holding.
  • Paradigm Biocapital Advisors first reported a position in Revolution Medicines in Q1 2024 and has held it in 9 quarters since.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2026, filed 15 May 2026.